FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130776984> ?p ?o ?g. }

• W2130776984 endingPage "S160" @default.
• W2130776984 startingPage "S153" @default.
• W2130776984 abstract "Pregnancy in type 1 and type 2 diabetes mellitus (DM) is associated with an increased rate of adverse outcomes for both mother and fetus.This article reviews the data available on achieving better outcomes in pregnancies complicated by DM.Background materials for this article were gathered based on a PubMed search of English-language articles (up to and including August 2007) using the search terms diabetes mellitus, pregnancy, glycemic control, mortality, and morbidity. This review article was based on a presentation given at a satellite symposium entitled Realising the Value of Modern Insulins: Reaching Further with Rapid-Acting Insulin Analogues that was convened during the XIXth World Diabetes Congress, December 3, 2006, in Cape Town, South Africa.There is clear evidence that optimized metabolic control, from preconception through pregnancy, can reduce the risk of maternal and fetal complications in women with DM. The risk of fetal congenital abnormalities in pregnant women with DM is intricately related to the level of glycemic control in early pregnancy; thus, strict metabolic targets as close to normal glycosylated hemoglobin (HbA1c) (ie, 4.0%-6.0%) as possible are recommended. However, these HbA1c and postprandial plasma glucose targets are challenging for the physician and the patient. The rapid-acting insulin analogues, insulin aspart and insulin lispro, may be useful because they can reduce postprandial hyperglycemia without increasing the risk for hypoglycemia and even provide a small improvement in HbA1c compared with regular human insulin. In a recent, prospective, randomized controlled study of pregnant women with type 1 DM (N=322), maternal hypoglycemia, metabolic control, and tolerability, including perinatal outcomes, were compared between those randomized to mealtime insulin aspart or human insulin. The results from this study suggest that insulin aspart is at least as effective and well tolerated as human insulin in basal-bolus therapy with neutral protamine Hagedorn insulin. Overall, 80% of study participants in both groups achieved HbA1c levels<or=6.5% in the second trimester. In addition, insulin aspart was associated with lowered postprandial blood glucose levels, as well as reduced risk of hypoglycemia, suggesting that it may offer clinical advantages in this population.Women with DM who are of reproductive age should be identified as members of a high-risk group. Access to specialized prepregnancy clinics should be made available where their DM can be intensively managed throughout pregnancy by a combined obstetrical/endocrine multidisciplinary team. Use of multiple insulin injection regimens, including use of insulin aspart during pregnancy, is both well tolerated and effective and may offer some benefits with respect to postprandial glycemic control." @default.
• W2130776984 created "2016-06-24" @default.
• W2130776984 creator A5059057421 @default.
• W2130776984 date "2007-01-01" @default.
• W2130776984 modified "2023-10-01" @default.
• W2130776984 title "Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus" @default.
• W2130776984 cites W1951862796 @default.
• W2130776984 cites W1969229725 @default.
• W2130776984 cites W1969457947 @default.
• W2130776984 cites W1982246457 @default.
• W2130776984 cites W1993084730 @default.
• W2130776984 cites W1993305086 @default.
• W2130776984 cites W1998682593 @default.
• W2130776984 cites W2008480352 @default.
• W2130776984 cites W2010598445 @default.
• W2130776984 cites W2013495500 @default.
• W2130776984 cites W2030458627 @default.
• W2130776984 cites W2030768028 @default.
• W2130776984 cites W2030928973 @default.
• W2130776984 cites W2039235849 @default.
• W2130776984 cites W2049068012 @default.
• W2130776984 cites W2062149394 @default.
• W2130776984 cites W2063434715 @default.
• W2130776984 cites W2063568309 @default.
• W2130776984 cites W2065009448 @default.
• W2130776984 cites W2065150378 @default.
• W2130776984 cites W2066807346 @default.
• W2130776984 cites W2073049443 @default.
• W2130776984 cites W2084744907 @default.
• W2130776984 cites W2089983694 @default.
• W2130776984 cites W2091386003 @default.
• W2130776984 cites W2102410486 @default.
• W2130776984 cites W2102955736 @default.
• W2130776984 cites W2107887942 @default.
• W2130776984 cites W2108986141 @default.
• W2130776984 cites W2115067299 @default.
• W2130776984 cites W2122601451 @default.
• W2130776984 cites W2127443317 @default.
• W2130776984 cites W2129752055 @default.
• W2130776984 cites W2156674980 @default.
• W2130776984 cites W2160394897 @default.
• W2130776984 cites W2315491743 @default.
• W2130776984 cites W2409528357 @default.
• W2130776984 cites W2769264260 @default.
• W2130776984 cites W1996815206 @default.
• W2130776984 doi "https://doi.org/10.1016/j.clinthera.2007.12.015" @default.
• W2130776984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18191067" @default.
• W2130776984 hasPublicationYear "2007" @default.
• W2130776984 type Work @default.
• W2130776984 sameAs 2130776984 @default.
• W2130776984 citedByCount "71" @default.
• W2130776984 countsByYear W21307769842012 @default.
• W2130776984 countsByYear W21307769842013 @default.
• W2130776984 countsByYear W21307769842014 @default.
• W2130776984 countsByYear W21307769842015 @default.
• W2130776984 countsByYear W21307769842016 @default.
• W2130776984 countsByYear W21307769842017 @default.
• W2130776984 countsByYear W21307769842018 @default.
• W2130776984 countsByYear W21307769842019 @default.
• W2130776984 countsByYear W21307769842020 @default.
• W2130776984 countsByYear W21307769842021 @default.
• W2130776984 countsByYear W21307769842022 @default.
• W2130776984 countsByYear W21307769842023 @default.
• W2130776984 crossrefType "journal-article" @default.
• W2130776984 hasAuthorship W2130776984A5059057421 @default.
• W2130776984 hasConcept C126322002 @default.
• W2130776984 hasConcept C131872663 @default.
• W2130776984 hasConcept C134018914 @default.
• W2130776984 hasConcept C177713679 @default.
• W2130776984 hasConcept C187212893 @default.
• W2130776984 hasConcept C2777180221 @default.
• W2130776984 hasConcept C2777986614 @default.
• W2130776984 hasConcept C2778199505 @default.
• W2130776984 hasConcept C2779234561 @default.
• W2130776984 hasConcept C2779306644 @default.
• W2130776984 hasConcept C2779434492 @default.
• W2130776984 hasConcept C2780473172 @default.
• W2130776984 hasConcept C2780668416 @default.
• W2130776984 hasConcept C2781232474 @default.
• W2130776984 hasConcept C2910068830 @default.
• W2130776984 hasConcept C46973012 @default.
• W2130776984 hasConcept C54355233 @default.
• W2130776984 hasConcept C555293320 @default.
• W2130776984 hasConcept C71924100 @default.
• W2130776984 hasConcept C86803240 @default.
• W2130776984 hasConceptScore W2130776984C126322002 @default.
• W2130776984 hasConceptScore W2130776984C131872663 @default.
• W2130776984 hasConceptScore W2130776984C134018914 @default.
• W2130776984 hasConceptScore W2130776984C177713679 @default.
• W2130776984 hasConceptScore W2130776984C187212893 @default.
• W2130776984 hasConceptScore W2130776984C2777180221 @default.
• W2130776984 hasConceptScore W2130776984C2777986614 @default.
• W2130776984 hasConceptScore W2130776984C2778199505 @default.
• W2130776984 hasConceptScore W2130776984C2779234561 @default.
• W2130776984 hasConceptScore W2130776984C2779306644 @default.
• W2130776984 hasConceptScore W2130776984C2779434492 @default.
• W2130776984 hasConceptScore W2130776984C2780473172 @default.
• W2130776984 hasConceptScore W2130776984C2780668416 @default.

• next